IL17A and histiocytic sarcoma: Currently, four Phase III randomized, controlled clinical trials are ongoing, the results of which will affirm the role of anti‐IL‐17 therapy in moderate‐to‐severe HS (secukinumab: SUNSHINE [NCT03713619], SUNRISE, [NCT03713632]; bimekizumab: BE HEARD I [NCT04242446], BE HEARD II [NCT04242498]).